![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Previous studies from our laboratory suggest the presence of toxic factor(s) in the cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS) which induces degenerative changes in the spinal cord neurons. The present work was carried out to investigate the role of (‐)‐deprenyl in attenuating these degenerative changes. CSF samples from ALS and non‐ALS neurological patients were injected into the spinal subarachnoid space of 3‐day‐old rat pups, followed by a single dose (0.01 mg/kg body weight) of (‐)‐deprenyl, administered 24 h after CSF injection. After a further period of 24 h, the rats were sacrificed and the spinal cord sections were stained with antibodies against phosphorylated neurofilament (NF, SMI‐31 antibody) and glial fibrillary acidic protein (GFAP). Activity of lactate dehydrogenase (LDH) was also measured. (‐)‐Deprenyl injection resulted in a significant (61%) decrease in the number of SMI‐31 stained neuronal soma in the ventral horn of the spinal cord of ALS CSF exposed rats. This was accompanied by a reduction in the astrocytes immunoreactive for GFAP. There was also a significant (35%) decrease in the LDH activity following (‐)‐deprenyl treatment. These results suggest that (‐)‐deprenyl may confer neuroprotection against the toxic factor(s) present in ALS CSF.